Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FYB203 biosimilar vs Eylea in neovascular AMD
NCT04522167Phase 3Completed
- Sponsor
- Bioeq AG
- Start
- Jul 2020
- Primary completion
- Jun 2022
- Modality
- Fc-Fusion Proteins
- Countries
- 9
01
Overview
A Phase 3 trial of baiama in neovascular age-related macular degeneration (NVAMD), sponsored by Bioeq AG. Started Jul 2020; status: completed.
02
Drugs
baiama
03
Conditions
neovascular age-related macular degeneration (NVAMD)
Beyond the preview
Go deeper on NCT04522167.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04522167.